The Food and Drug Administration have approved the use of a special disposable pen for diabetic injections, put forward by Amylin Pharmaceuticals . The pen is designed to be used with Symli, a drug created by the company to help control blood sugar highs and lows amongst diabetics .
However, in a twist of fate, the FDA ruled that Symlin could not be used by those diabetic patients who use basal insulin. The FDA sent a ‘not approvable’ letter to Amylin outlining their decision. The injection pe, unlike insulin, can be stored at room temperature.
Amylin are not despairing about the decisio, and have already said that they will approach the FDA. The company said that the pens will come to market in December. Financial experts don’t expect the news to have too much impact on share prices.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…